Pharmaceutical

Request for TOC Request for Sample
BUY NOW

U.S. Rx Dermatology Topical Drug Delivery Market – Industry Trends and Forecast to 2030

Pharmaceutical | Upcoming Report | Jan 2023 | Country Level | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

U.S. Rx Dermatology Topical Drug Delivery Market, By Product Type (Semi-Solid, Liquid, Solid), Drug Class (Topical Corticosteroids, Anti-Septic, Anti-Acne, Anti-Inflammatory, Anti-Bacterial, Anti-Fungal, Antihistamines, Erythromycin, Wound Healing Agents, Others), Application (Atopic Dermatitis, Hyperpigmentation, Skin Cancer, Onychomycosis, Hidradenitis Suppurativa, Others), Category (Branded, Generic), Distribution Channel (Retail Pharmacy & Drug Store, Hospital Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

 U.S. Rx Dermatology Topical Drug Delivery Market Analysis and Size

The increase in occurrences of burn injuries all over the world acts as one of the primary factors boosting the growth of Rx dermatology topical drug delivery market. It has been observed that transdermal products are estimated to witness huge growth rate during the forecast period 2023-2030. Rising incidence of skin diseases such as acne vulgaris has pushed the market to a great extent.

Data Bridge Market Research analyses a growth rate in the Rx dermatology topical drug delivery market in the forecast period 2023-2030. The expected CAGR of Rx dermatology topical drug delivery market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 41.5 billion in 2022, and it would grow upto USD 79.71 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. Rx Dermatology Topical Drug Delivery Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Semi-Solid, Liquid, Solid), Drug Class (Topical Corticosteroids, Anti-Septic, Anti-Acne, Anti-Inflammatory, Anti-Bacterial, Anti-Fungal, Antihistamines, Erythromycin, Wound Healing Agents, Others), Application (Atopic Dermatitis, Hyperpigmentation, Skin Cancer, Onychomycosis, Hidradenitis Suppurativa, Others), Category (Branded, Generic), Distribution Channel (Retail Pharmacy & Drug Store, Hospital Pharmacy, Online Pharmacy, Others)

Market Players Covered

Agouron Pharmaceuticals, LLC (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.) and G. D. Searle & Co. Limited (U.K.) Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Pfizer Inc.(U.S.), Fresenius Kabi AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland)

Market Opportunities

  • Increasing Advancements in Medicinal & Pharmacy Therapeutics

Market Definition

The Rx dermatology topical drug delivery is the type of topical drug delivery of a medication which is applied to a particular place on, or in the body. Bacterial and fungal infections, psoriasis, hair, skin, acne, inflammations, and skin problems are the type of indications it deals with. Topical drugs play an essential role in treating dermatologic diseases and comprise a large percentage of products in the drug sector.  

U.S. Rx Dermatology Topical Drug Delivery Market Dynamics

Drivers

  • Rising Prevalence of Fire Accidents

According to the study conducted by Value in Health journal, about 12,946 people in U.S. witnessed with complex burn injuries. Likewise, according to the report from National Fire Protection Association, local fire departments responded to about 1.4 million fire incidences in the U.S. Furthermore, home fires were witnessed every year and above 450,000 serious burn injuries are recorded in the U.S. alone as per American Burn Association. All these factors also contribute to the growth of the marketa as the demand for topical drug delivery is rising. Thus, this boost the growth of the treatment market.

  • Growing Cases of Skin Disorders

The rising frequency of skin cancer and other related skin disorders or other skin issues such as acne, vitiligo, and dermatosis combined with the increasing demand of effective drugs are the most prominent factors boosting the growth for this market. Additionally, fungal infection and acne were more incident in the adolescent age group, accounting for about 17.4% and 30.4%, respectively. About 84.5 million Americans, one in four, were largely impacted by skin disease. It has been seen that acne is the most common skin condition in the U.S., affecting more than 50 million Americans each year. Acne typically begins in puberty and affects numerous adolescents and young adults. According to the records of the World Psoriasis Day consortium, about 125 million people globally which means that 2 to 3% of the total population suffer from psoriasis. Thus, this boosts the market growth.  

Opportunities

  • Increasing Advancements in Medicinal & Pharmacy Therapeutics

Huge advancements in medicinal and pharmacy therapeutics associated with skin and burn accidents are pushing the market. For instance, Biofrontera AG has received U.S. Food and Drug Administration for acclerating the batch production of Ameluz to 35 kg from 7 kg in past years in January. Biofrontera AG has also got approval from the European Medicines Agency (EMA). This fivefold increase in the production of Ameluz benefits Biofrontera AG to meet the increasing requirement for Ameluz globally. Therefore, these factors are anticipated to fuel the market during the forecast period 2023-2030.

Restraints/Challenges

  • Side-Effects of Drug Delivery Process

Numerous side-effects are related to the disease, such as nausea, dizziness, or headache. Also, stinging, irritation, burning, dryness, or redness at the application site may occur. Thus, these factors restrict the market growth.

This Rx dermatology topical drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Rx dermatology topical drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

U.S. Rx Dermatology Topical Drug Delivery Market Scope

The Rx dermatology topical drug delivery market is segmented on the basis of product type, drug class, application, category, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Semi-Solid
  • Liquid
  • Solid

Drug Class

  • Topical Corticosteroids
  • Anti-Septic
  • Anti-Acne
  • Anti-Inflammatory
  • Anti-Bacterial
  • Anti-Fungal
  • Antihistamines
  • Erythromycin
  • Wound Healing Agents
  • Others

Application

  • Atopic Dermatitis
  • Hyperpigmentation
  • Skin Cancer
  • Onychomycosis
  • Hidradenitis Suppurativa
  • Others

Category

  • Branded
  • Generic

End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

Distribution Channel

  • Retail Pharmacy & Drug Store
  • Hospital Pharmacy
  • Online Pharmacy
  • Others

Competitive Landscape and U.S. Rx Dermatology Topical Drug Delivery Market Share Analysis

The Rx dermatology topical drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Rx dermatology topical drug delivery market.

Key players operating in the Rx dermatology topical drug delivery market include:

  • Agouron Pharmaceuticals, LLC (U.S.)
  • AHP Holdings B.V. (Netherlands)
  • Alacer Corp. (U.S.)
  • Alpharma Pharmaceuticals LLC (U.S.)
  • Bioren, LLC (U.S.)
  • G. D. Searle & Co. Limited (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Mylan N.V.(U.S.)
  • Pfizer Inc.(U.S.)
  • Fresenius Kabi AG (Germany)
  • F. Hoffmann-La Roche Ltd. (Switzerland)


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19